AI Insight
This is a correction notice for a previously published randomized controlled trial that investigated the use of valganciclovir as an empirical treatment for infants living with HIV who were hospitalized with severe pneumonia in Africa. The correction updates the acknowledgments section to properly recognize the contribution of the UK Department of Health and Social Care through the UK National Institute for Health and Care Research, in addition to the previously acknowledged European and Developing Countries Clinical Trials Partnership grant.
Why it matters
This correction ensures proper attribution of funding sources for the research, which is important for transparency in clinical trials. Accurate acknowledgment of funding bodies is essential for maintaining research integrity and recognizing institutional contributions to scientific work.
Understand the Science
Moraleda C, Tagarro A, Domínguez-Rodríguez S, et al. Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial. Lancet 2026; published online July 17. https://doi.org/10.1016/S0140-6736(26)00754-3—In this Article, the Acknowledgment relating to the European and Developing Countries Clinical Trials Partnership grant has been updated to include acknowledgment of the contribution of the UK Department of Health and Social Care through the UK National Institute for Health and Care Research.